Antihistamine use and immunoglobulin E levels in glioma risk and prognosis
Abstract Objective: An inverse association between personal history of allergies/asthma and glioma risk has been fairly consistently reported in the epidemiologic literature. However, the role of regular antihistamine use remains controversial due to a small number of studies reporting contradictory...
Gespeichert in:
Veröffentlicht in: | Cancer epidemiology 2013-12, Vol.37 (6), p.908-912 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 912 |
---|---|
container_issue | 6 |
container_start_page | 908 |
container_title | Cancer epidemiology |
container_volume | 37 |
creator | Amirian, E. Susan Marquez-Do, Deborah Bondy, Melissa L Scheurer, Michael E |
description | Abstract Objective: An inverse association between personal history of allergies/asthma and glioma risk has been fairly consistently reported in the epidemiologic literature. However, the role of regular antihistamine use remains controversial due to a small number of studies reporting contradictory findings. We evaluated the association between regular use of oral antihistamines and glioma risk, adjusting for a number of relevant factors (e.g., immunoglobulin E levels and history of chickenpox). Methods : We used a subset of the Harris County Case-Control Study, which included 362 pathologically confirmed glioma cases and 462 cancer-free controls, to evaluate this association using unconditional multivariable logistic regression. These models were run among the overall study population and stratified by allergy status. Cox regression was utilized to examine whether antihistamine use was associated with mortality among all cases and separately among high-grade cases. Results : Antihistamine use was strongly associated with glioma risk among those with a positive allergy/asthma history (OR: 4.19, 95% CI: 2.06–8.51), but not among those with a negative history (OR: 1.59, 95% CI: 0.95–2.67). There were no significant associations between antihistamine use and survival among cases. Conclusion : The current study implies that regular antihistamine use may increase glioma risk. However, several larger studies are necessary before definitive conclusions can be drawn. |
doi_str_mv | 10.1016/j.canep.2013.08.004 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3851921</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1877782113001197</els_id><sourcerecordid>3146116821</sourcerecordid><originalsourceid>FETCH-LOGICAL-c605t-3263df58628e92a0b7d5e2d56c68ba619d3d6c54eb45c008ee32f8567c206fe3</originalsourceid><addsrcrecordid>eNqFkk1r3DAQhk1padK0v6BQDCXQy7ojyZLlQwMhpF8EemgOvQmtPN5oI0tbyV7Iv6-c3W7aXHLSgJ75eOedonhLoCJAxMd1ZbTHTUWBsApkBVA_K46JbJpFI9mv54eYkqPiVUprACEI4S-LI8ratqZSHBffz_1ob2wa9WA9llPCUvuutMMw-bByYTk568vL0uEWXSpzvHI2DLqMNt3eo5sYVj4km14XL3rtEr7ZvyfF9efL64uvi6sfX75dnF8tjAA-LhgVrOu5FFRiSzUsm44j7bgwQi61IG3HOmF4jcuaGwCJyGgvuWgMBdEjOynOdmU303LAzqAfo3ZqE-2g450K2qr_f7y9UauwVUxy0lKSC3zYF4jh94RpVINNBp3L2wxTUoQDNHk_hD2N1qJuCTDSZvT9I3QdpujzInaUqDmVmWI7ysSQUsT-MDcBNbuq1ureVTW7qkCq7GrOevev5EPOXxszcLoHdDLa9VF7Y9MDJ4HWNZ_1fNpx2UvcWowqGYveYGcjmlF1wT4xyNmjfJPPw-aWt3iH6UGxSlSB-jkf4Hx_hAEQ0jbsD3Zi1cc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1464964528</pqid></control><display><type>article</type><title>Antihistamine use and immunoglobulin E levels in glioma risk and prognosis</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><source>ProQuest Central UK/Ireland</source><creator>Amirian, E. Susan ; Marquez-Do, Deborah ; Bondy, Melissa L ; Scheurer, Michael E</creator><creatorcontrib>Amirian, E. Susan ; Marquez-Do, Deborah ; Bondy, Melissa L ; Scheurer, Michael E</creatorcontrib><description>Abstract Objective: An inverse association between personal history of allergies/asthma and glioma risk has been fairly consistently reported in the epidemiologic literature. However, the role of regular antihistamine use remains controversial due to a small number of studies reporting contradictory findings. We evaluated the association between regular use of oral antihistamines and glioma risk, adjusting for a number of relevant factors (e.g., immunoglobulin E levels and history of chickenpox). Methods : We used a subset of the Harris County Case-Control Study, which included 362 pathologically confirmed glioma cases and 462 cancer-free controls, to evaluate this association using unconditional multivariable logistic regression. These models were run among the overall study population and stratified by allergy status. Cox regression was utilized to examine whether antihistamine use was associated with mortality among all cases and separately among high-grade cases. Results : Antihistamine use was strongly associated with glioma risk among those with a positive allergy/asthma history (OR: 4.19, 95% CI: 2.06–8.51), but not among those with a negative history (OR: 1.59, 95% CI: 0.95–2.67). There were no significant associations between antihistamine use and survival among cases. Conclusion : The current study implies that regular antihistamine use may increase glioma risk. However, several larger studies are necessary before definitive conclusions can be drawn.</description><identifier>ISSN: 1877-7821</identifier><identifier>EISSN: 1877-783X</identifier><identifier>DOI: 10.1016/j.canep.2013.08.004</identifier><identifier>PMID: 23994286</identifier><language>eng</language><publisher>Amsterdam: Elsevier Ltd</publisher><subject>Adolescent ; Adult ; Age ; Allergies ; Analysis. Health state ; Asthma ; Biological and medical sciences ; Brain neoplasms ; Brain Neoplasms - blood ; Brain Neoplasms - epidemiology ; Brain Neoplasms - pathology ; Cancer ; Cancer therapies ; Case-Control Studies ; Chemotherapy ; Confidence intervals ; Enzyme-Linked Immunosorbent Assay ; Epidemiology ; Female ; Follow-Up Studies ; General aspects ; Glioma - blood ; Glioma - epidemiology ; Glioma - pathology ; Hematology, Oncology and Palliative Medicine ; Histamine Antagonists - therapeutic use ; Humans ; Hypersensitivity ; Immunoglobulin E ; Immunoglobulin E - blood ; Internal Medicine ; Logistics ; Male ; Medical sciences ; Middle Aged ; Neoplasm Grading ; Population ; Prognosis ; Public health. Hygiene ; Public health. Hygiene-occupational medicine ; Risk Factors ; Studies ; Survival ; Survival Rate ; Tumors ; Young Adult</subject><ispartof>Cancer epidemiology, 2013-12, Vol.37 (6), p.908-912</ispartof><rights>Elsevier Ltd</rights><rights>2013 Elsevier Ltd</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2013 Elsevier Ltd. All rights reserved.</rights><rights>Copyright Elsevier Limited 2013</rights><rights>2013 Elsevier Inc. All rights reserved. 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c605t-3263df58628e92a0b7d5e2d56c68ba619d3d6c54eb45c008ee32f8567c206fe3</citedby><cites>FETCH-LOGICAL-c605t-3263df58628e92a0b7d5e2d56c68ba619d3d6c54eb45c008ee32f8567c206fe3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1464964528?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>230,314,780,784,885,3548,27923,27924,45994,64384,64386,64388,72240</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28024453$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23994286$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Amirian, E. Susan</creatorcontrib><creatorcontrib>Marquez-Do, Deborah</creatorcontrib><creatorcontrib>Bondy, Melissa L</creatorcontrib><creatorcontrib>Scheurer, Michael E</creatorcontrib><title>Antihistamine use and immunoglobulin E levels in glioma risk and prognosis</title><title>Cancer epidemiology</title><addtitle>Cancer Epidemiol</addtitle><description>Abstract Objective: An inverse association between personal history of allergies/asthma and glioma risk has been fairly consistently reported in the epidemiologic literature. However, the role of regular antihistamine use remains controversial due to a small number of studies reporting contradictory findings. We evaluated the association between regular use of oral antihistamines and glioma risk, adjusting for a number of relevant factors (e.g., immunoglobulin E levels and history of chickenpox). Methods : We used a subset of the Harris County Case-Control Study, which included 362 pathologically confirmed glioma cases and 462 cancer-free controls, to evaluate this association using unconditional multivariable logistic regression. These models were run among the overall study population and stratified by allergy status. Cox regression was utilized to examine whether antihistamine use was associated with mortality among all cases and separately among high-grade cases. Results : Antihistamine use was strongly associated with glioma risk among those with a positive allergy/asthma history (OR: 4.19, 95% CI: 2.06–8.51), but not among those with a negative history (OR: 1.59, 95% CI: 0.95–2.67). There were no significant associations between antihistamine use and survival among cases. Conclusion : The current study implies that regular antihistamine use may increase glioma risk. However, several larger studies are necessary before definitive conclusions can be drawn.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Age</subject><subject>Allergies</subject><subject>Analysis. Health state</subject><subject>Asthma</subject><subject>Biological and medical sciences</subject><subject>Brain neoplasms</subject><subject>Brain Neoplasms - blood</subject><subject>Brain Neoplasms - epidemiology</subject><subject>Brain Neoplasms - pathology</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Case-Control Studies</subject><subject>Chemotherapy</subject><subject>Confidence intervals</subject><subject>Enzyme-Linked Immunosorbent Assay</subject><subject>Epidemiology</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>General aspects</subject><subject>Glioma - blood</subject><subject>Glioma - epidemiology</subject><subject>Glioma - pathology</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Histamine Antagonists - therapeutic use</subject><subject>Humans</subject><subject>Hypersensitivity</subject><subject>Immunoglobulin E</subject><subject>Immunoglobulin E - blood</subject><subject>Internal Medicine</subject><subject>Logistics</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neoplasm Grading</subject><subject>Population</subject><subject>Prognosis</subject><subject>Public health. Hygiene</subject><subject>Public health. Hygiene-occupational medicine</subject><subject>Risk Factors</subject><subject>Studies</subject><subject>Survival</subject><subject>Survival Rate</subject><subject>Tumors</subject><subject>Young Adult</subject><issn>1877-7821</issn><issn>1877-783X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkk1r3DAQhk1padK0v6BQDCXQy7ojyZLlQwMhpF8EemgOvQmtPN5oI0tbyV7Iv6-c3W7aXHLSgJ75eOedonhLoCJAxMd1ZbTHTUWBsApkBVA_K46JbJpFI9mv54eYkqPiVUprACEI4S-LI8ratqZSHBffz_1ob2wa9WA9llPCUvuutMMw-bByYTk568vL0uEWXSpzvHI2DLqMNt3eo5sYVj4km14XL3rtEr7ZvyfF9efL64uvi6sfX75dnF8tjAA-LhgVrOu5FFRiSzUsm44j7bgwQi61IG3HOmF4jcuaGwCJyGgvuWgMBdEjOynOdmU303LAzqAfo3ZqE-2g450K2qr_f7y9UauwVUxy0lKSC3zYF4jh94RpVINNBp3L2wxTUoQDNHk_hD2N1qJuCTDSZvT9I3QdpujzInaUqDmVmWI7ysSQUsT-MDcBNbuq1ureVTW7qkCq7GrOevev5EPOXxszcLoHdDLa9VF7Y9MDJ4HWNZ_1fNpx2UvcWowqGYveYGcjmlF1wT4xyNmjfJPPw-aWt3iH6UGxSlSB-jkf4Hx_hAEQ0jbsD3Zi1cc</recordid><startdate>20131201</startdate><enddate>20131201</enddate><creator>Amirian, E. Susan</creator><creator>Marquez-Do, Deborah</creator><creator>Bondy, Melissa L</creator><creator>Scheurer, Michael E</creator><general>Elsevier Ltd</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>7T2</scope><scope>7T5</scope><scope>7U1</scope><scope>7U2</scope><scope>C1K</scope><scope>5PM</scope></search><sort><creationdate>20131201</creationdate><title>Antihistamine use and immunoglobulin E levels in glioma risk and prognosis</title><author>Amirian, E. Susan ; Marquez-Do, Deborah ; Bondy, Melissa L ; Scheurer, Michael E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c605t-3263df58628e92a0b7d5e2d56c68ba619d3d6c54eb45c008ee32f8567c206fe3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Age</topic><topic>Allergies</topic><topic>Analysis. Health state</topic><topic>Asthma</topic><topic>Biological and medical sciences</topic><topic>Brain neoplasms</topic><topic>Brain Neoplasms - blood</topic><topic>Brain Neoplasms - epidemiology</topic><topic>Brain Neoplasms - pathology</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Case-Control Studies</topic><topic>Chemotherapy</topic><topic>Confidence intervals</topic><topic>Enzyme-Linked Immunosorbent Assay</topic><topic>Epidemiology</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>General aspects</topic><topic>Glioma - blood</topic><topic>Glioma - epidemiology</topic><topic>Glioma - pathology</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Histamine Antagonists - therapeutic use</topic><topic>Humans</topic><topic>Hypersensitivity</topic><topic>Immunoglobulin E</topic><topic>Immunoglobulin E - blood</topic><topic>Internal Medicine</topic><topic>Logistics</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neoplasm Grading</topic><topic>Population</topic><topic>Prognosis</topic><topic>Public health. Hygiene</topic><topic>Public health. Hygiene-occupational medicine</topic><topic>Risk Factors</topic><topic>Studies</topic><topic>Survival</topic><topic>Survival Rate</topic><topic>Tumors</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Amirian, E. Susan</creatorcontrib><creatorcontrib>Marquez-Do, Deborah</creatorcontrib><creatorcontrib>Bondy, Melissa L</creatorcontrib><creatorcontrib>Scheurer, Michael E</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Risk Abstracts</collection><collection>Safety Science and Risk</collection><collection>Environmental Sciences and Pollution Management</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer epidemiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Amirian, E. Susan</au><au>Marquez-Do, Deborah</au><au>Bondy, Melissa L</au><au>Scheurer, Michael E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antihistamine use and immunoglobulin E levels in glioma risk and prognosis</atitle><jtitle>Cancer epidemiology</jtitle><addtitle>Cancer Epidemiol</addtitle><date>2013-12-01</date><risdate>2013</risdate><volume>37</volume><issue>6</issue><spage>908</spage><epage>912</epage><pages>908-912</pages><issn>1877-7821</issn><eissn>1877-783X</eissn><abstract>Abstract Objective: An inverse association between personal history of allergies/asthma and glioma risk has been fairly consistently reported in the epidemiologic literature. However, the role of regular antihistamine use remains controversial due to a small number of studies reporting contradictory findings. We evaluated the association between regular use of oral antihistamines and glioma risk, adjusting for a number of relevant factors (e.g., immunoglobulin E levels and history of chickenpox). Methods : We used a subset of the Harris County Case-Control Study, which included 362 pathologically confirmed glioma cases and 462 cancer-free controls, to evaluate this association using unconditional multivariable logistic regression. These models were run among the overall study population and stratified by allergy status. Cox regression was utilized to examine whether antihistamine use was associated with mortality among all cases and separately among high-grade cases. Results : Antihistamine use was strongly associated with glioma risk among those with a positive allergy/asthma history (OR: 4.19, 95% CI: 2.06–8.51), but not among those with a negative history (OR: 1.59, 95% CI: 0.95–2.67). There were no significant associations between antihistamine use and survival among cases. Conclusion : The current study implies that regular antihistamine use may increase glioma risk. However, several larger studies are necessary before definitive conclusions can be drawn.</abstract><cop>Amsterdam</cop><pub>Elsevier Ltd</pub><pmid>23994286</pmid><doi>10.1016/j.canep.2013.08.004</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1877-7821 |
ispartof | Cancer epidemiology, 2013-12, Vol.37 (6), p.908-912 |
issn | 1877-7821 1877-783X |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3851921 |
source | MEDLINE; ScienceDirect Journals (5 years ago - present); ProQuest Central UK/Ireland |
subjects | Adolescent Adult Age Allergies Analysis. Health state Asthma Biological and medical sciences Brain neoplasms Brain Neoplasms - blood Brain Neoplasms - epidemiology Brain Neoplasms - pathology Cancer Cancer therapies Case-Control Studies Chemotherapy Confidence intervals Enzyme-Linked Immunosorbent Assay Epidemiology Female Follow-Up Studies General aspects Glioma - blood Glioma - epidemiology Glioma - pathology Hematology, Oncology and Palliative Medicine Histamine Antagonists - therapeutic use Humans Hypersensitivity Immunoglobulin E Immunoglobulin E - blood Internal Medicine Logistics Male Medical sciences Middle Aged Neoplasm Grading Population Prognosis Public health. Hygiene Public health. Hygiene-occupational medicine Risk Factors Studies Survival Survival Rate Tumors Young Adult |
title | Antihistamine use and immunoglobulin E levels in glioma risk and prognosis |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T12%3A42%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antihistamine%20use%20and%20immunoglobulin%20E%20levels%20in%20glioma%20risk%20and%20prognosis&rft.jtitle=Cancer%20epidemiology&rft.au=Amirian,%20E.%20Susan&rft.date=2013-12-01&rft.volume=37&rft.issue=6&rft.spage=908&rft.epage=912&rft.pages=908-912&rft.issn=1877-7821&rft.eissn=1877-783X&rft_id=info:doi/10.1016/j.canep.2013.08.004&rft_dat=%3Cproquest_pubme%3E3146116821%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1464964528&rft_id=info:pmid/23994286&rft_els_id=S1877782113001197&rfr_iscdi=true |